Further trials will be required to understand any potential clinical benefit for TSLP blockade in T2 low COPD populations, and studies incorporating airway biospecimen analysis are required to understand the impact on neutrophil-related inflammation and phenotypes. The gene discussed is TSLP; the disease is chronic obstructive pulmonary disease.